AstraZeneca razes R&D facilities in Delaware

AstraZeneca's ($AZN) former R&D operations in Delaware, abandoned years ago in the pharma giant's ongoing restructuring and downsizing, are being razed. The pharma giant says it is leveling three buildings that once comprised 450,000 square feet of research space. "Because we no longer carry out discovery or other laboratory research activities at this location, we are removing the buildings that were previously home to that R&D work, which has relocated to our other sites across the globe," the company said in a statement released to The News Journal. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.